REFINE-Lung trial: what clinicians have said so far
A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
- NCT05085028 ↗
- Recruiting
- Imperial College London
- Standard size, estimated: 151–300 verified statements once built
We haven't built an HCP commentary report on REFINE-Lung (pembrolizumab in first-line advanced non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on REFINE-Lung so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 11 posts on X, typically up to 48 once built | |
| 3 podcast episodes, typically up to 13 once built | |
| 1 YouTube video, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Utilising a Novel Multi-arm Frequency-response Optimisation Design
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Lung Cancer, Nonsmall Cell
- Interventions
- Pembrolizumab 25 MG/ML [Keytruda]
- Arms
- 6 weekly · Active comparator
- 9 weekly · Experimental
- 12 weekly · Experimental
- 15 weekly · Experimental
- 18 weekly · Experimental
- Enrollment
- 1,750 (estimated)
- Primary outcomes
- Overall survival at 2 years
- Sponsor
- Imperial College London with National Institute for Health Research, United Kingdom, Medical Research Council, University College, London
- Start
- Jun 23, 2022
- Primary completion
- May 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05085028 · updated Mar 7, 2024
Publications
linked from the registry- Ghorani E, Quartagno M, Blackhall F, Gilbert DC, O'Brien M, Ottensmeier C, Pizzo E, Spicer J, Williams A, Badman P, Parmar MKB, Seckl MJ; REFINE-Lung Investigators. REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment. Lancet Oncol. 2023 May;24(5):e219-e227. doi: 10.1016/S1470-2045(23)00095-5. PubMed 37142383